Use of acetylcholinesterase inhibitors in Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 1, Issue 1, 2001, Pages 61-69

  Moghul, Shehram ^a   Wilkinson, David ^a  

^a MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Acethylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Galantamine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; VELNACRINE;

ALZHEIMER DISEASE; BEHAVIOR; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL SYMPTOM; HUMAN; LEWY BODY; LIVER TOXICITY; MULTIINFARCT DEMENTIA; MUSCLE WEAKNESS; REVIEW;

EID: 0035741357     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.1.61     Document Type: Review

References (65)

1. Donepezil improves cognition and global function in Alzheimer's Disease
2. Selective loss of central cholinergic neurons in Alzheimer's Disease
3. The cholinergic hypothesis of geriatric memory dysfunction
4. Drugs for the treatment of Alzheimer's Disease
5. Molecular biology of Alzheimer's Disease
6. A controlled trial of tacrine in AD
7. A 30 week randomized controlled trial of high dose tacrine in patients with AD
8. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study
9. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease
10. Clinical development of metrifonate: An overview of cognitive and global outcomes
11. Donepezil improves cognition and global function in Alzheimer's disease. A 15 week, double-blind, placebo-controlled study
12. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
13. The effects of donepezil in Alzheimer's disease-results from a multinational trial
14. A tandomised trial evaluating the efficacy and safety of ENA 173 (tivastigmine tartate) a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease
15. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: Intetnational randomised controlled trial
16. Galantamine: A randomized double-blind, dose-finding trial in patients with Alzheimer's disease
17. Galantamine in Alzheimer's disease: A 6-month randomized, placebo-controlled trial with a 6-month extension
18. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: Multicentre, randomised controlled trial
19. Oral tetrahydroaminoacridiine in long-term treatment of senile dementia, Alzheimer type
20. A 30 week randomized controlled trial of high dose tacrine in patients with AD
21. Hepatotoxic effects of tacrine administration in patients with Alzheimer's Disease
22. A double-blind, placebo-controlled, multicenter study of tacrine for Alzheimer's Disease
23. Cholinesterase Inhibition for AD
24. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's Disease
25. Metrifonate treatment of the cognitive deficits of Alzheimer's Disease
26. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's Disease
27. A multi-center, randomised, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's Disease: The MALT study
28. The impact of metrifonate therapy on caregivers of patients with AD: Results from the MALT clinical trial
29. The pharmacology of donepezil: A new treatment for Alzheimer's Disease
30. Donepezil for mild and moderate Alzheimer's Disease (Cochrane Review)
31. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
32. A new taring scale for Alzheimer's Disease
33. Validity and reliability of the Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change
34. Donepezil enhances global function, cognition and activities if daily living compared with placebo in a one-year, double-blind trial in patients with mild-to-moderate Alzheimer's disease
35. How useful are cholinesterase inhibitors in the treatment of Alzheimer's Disease? A number needed to treat analysis
36. The number needed to treat: A clinically useful measure of treatment effect
37. Rivastigmine for Alzheimer's Disease (Cochrane Review)
38. Galantamine for Alzheimer's Disease (Cochrane Review)
39. Drugs for Alzheimer's disease
40. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's Disease
41. The impact of metrifonate therapy on caregivers' of patients with Alzheimer's Disease: Results from the MALT clinical trial
42. Mental and behavioral disturbances in dementia: Findings from the Lache County Study of Memory in Ageing
43. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
44. Neuropsychiatric aspects of Alzheimer's Disease: The Cholinergic hypothesis revisited
45. A 5 month, randomized, placebo-controlled trial of galantamine in Alzheimer's Disease
46. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
47. A 1 -year placebo-controlled preservation of function survival study of donepezil in AD patients
48. The consortium to establish a registry for Alzheimer's disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease
49. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy Bodies
50. Efficacy of rivastigmine in dementia with Lewy bodies: A tandomised, double-blind, placebo-controlled international study
51. Donepezil for behavioral disorders associated with Lewy bodies: A case series
52. The US economic and social costs of Alzheimer's Disease revisited
53. An economic evaluation of donepezil in the treatment of Alzheimer's Disease
54. Long-term tacrine (Cognex®) treatment: Effects on nursing home placement and mortality
55. An economic evaluation of donepezil in the treatment of Alzheimer's disease
56. The economic consequences of Alzheimer's disease in the context of new drug developments
57. A 24-week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer's disease
58. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial